23.27
-2.51%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Henan Lingrui Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600285.SS. It has been listed since 18 October 2000. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.85bn and net income of CN¥759.5m. At that date it held total assets of CN¥5.64bn and shareholders' equity of CN¥3.40bn.
Henan Lingrui Pharmaceutical Co., Ltd. engages in the production and sale of medicine and health products. The company is headquartered in Xinyang, Henan. The company went IPO on 2000-10-18. The firm's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The firm distributes its products throughout China, with Henan Province and Beijing as its major markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 18 Oct 2000
- Employees
- 2,524
- Website
- lingrui.com ↗
Leadership
Pay as last reported
- Mr. Jianjun ChengChairman of the Board, since 2005CN¥506,200
- Mr. Zirun PanChief Financial Officer, Director, since 2014
- Mr. Wei XiongGeneral Manager, Director, since 2013
- Ms. Yan ChenDeputy General Manager, Director, since 2011CN¥263,300
- Mr. Xizhen WuDeputy General Manager, Director, since 2006CN¥369,900
- Wei TangDeputy General Manager, since 2014CN¥316,600
- Hui XiaDeputy General ManagerCN¥289,900
- Mr. Qunbin WangDirectorCN¥12,000
- Weizheng XiongDirector, since 2014CN¥768,100
- Jun ZhangDirectorCN¥406,200
- Mr. Zhijun ZhaoDirector, since 2005CN¥424,300
- Mr. Haibo DuIndependent DirectorCN¥36,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Henan Lingrui Pharmaceutical employs 2524 employees in Xinyang, China.
- The company produces emplastrum, tablets, and capsules for diabetes treatment.
- Henan Province and Beijing are key markets for Henan Lingrui Pharmaceutical products.
Weaknesses
- Henan Lingrui Pharmaceutical has no international distribution beyond China.
- The company's product range is limited to domestic Chinese markets.
- Henan Lingrui Pharmaceutical's IPO was in 2000, indicating limited recent growth.
Opportunities
- Expanding into international markets could increase Henan Lingrui Pharmaceutical's global presence.
- Growing demand for diabetes treatments in China offers new opportunities.
- The firm's focus on cardiovascular and cerebrovascular diseases aligns with health trends.
Threats
- Competition from other Chinese pharmaceutical companies in Henan Province.
- Rising costs of raw materials for pharmaceutical production in China.
- Regulatory changes in the Chinese Health Care sector may impact operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.